全文获取类型
收费全文 | 50321篇 |
免费 | 7286篇 |
国内免费 | 1328篇 |
专业分类
耳鼻咽喉 | 193篇 |
儿科学 | 993篇 |
妇产科学 | 660篇 |
基础医学 | 2621篇 |
口腔科学 | 2356篇 |
临床医学 | 7785篇 |
内科学 | 5296篇 |
皮肤病学 | 782篇 |
神经病学 | 2400篇 |
特种医学 | 795篇 |
外国民族医学 | 9篇 |
外科学 | 4992篇 |
综合类 | 9301篇 |
现状与发展 | 6篇 |
一般理论 | 26篇 |
预防医学 | 4570篇 |
眼科学 | 756篇 |
药学 | 6648篇 |
469篇 | |
中国医学 | 5121篇 |
肿瘤学 | 3156篇 |
出版年
2024年 | 80篇 |
2023年 | 1136篇 |
2022年 | 1420篇 |
2021年 | 2955篇 |
2020年 | 3487篇 |
2019年 | 2534篇 |
2018年 | 2322篇 |
2017年 | 2682篇 |
2016年 | 2643篇 |
2015年 | 2258篇 |
2014年 | 3886篇 |
2013年 | 4253篇 |
2012年 | 3410篇 |
2011年 | 3509篇 |
2010年 | 2730篇 |
2009年 | 2428篇 |
2008年 | 2329篇 |
2007年 | 2395篇 |
2006年 | 2026篇 |
2005年 | 1680篇 |
2004年 | 1427篇 |
2003年 | 1285篇 |
2002年 | 1019篇 |
2001年 | 811篇 |
2000年 | 631篇 |
1999年 | 472篇 |
1998年 | 379篇 |
1997年 | 355篇 |
1996年 | 302篇 |
1995年 | 249篇 |
1994年 | 253篇 |
1993年 | 172篇 |
1992年 | 205篇 |
1991年 | 165篇 |
1990年 | 141篇 |
1989年 | 143篇 |
1988年 | 130篇 |
1987年 | 114篇 |
1986年 | 77篇 |
1985年 | 95篇 |
1984年 | 75篇 |
1983年 | 40篇 |
1982年 | 47篇 |
1981年 | 38篇 |
1980年 | 34篇 |
1979年 | 23篇 |
1978年 | 12篇 |
1977年 | 16篇 |
1976年 | 17篇 |
1975年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 162 毫秒
31.
Takafumi Koyama Toshio Shimizu Satoru Iwasa Yutaka Fujiwara Shunsuke Kondo Shigehisa Kitano Kan Yonemori Akihiko Shimomura Sakura Iizumi Tatsuya Sasaki Junji Furuse Noboru Yamamoto 《Cancer science》2020,111(2):571-579
Fibroblast growth factor receptors (FGFR) are a family of transmembrane receptor tyrosine kinases involved in regulating cellular processes. FGFR mutations are implicated in oncogenesis, representing therapeutic potential in the form of FGFR inhibitors. This phase I, first‐in‐human study in Japan evaluated safety and tolerability of E7090, a potent selective FGFR1‐3 inhibitor, in patients with advanced solid tumors. Dose escalation (daily oral dose of 1‐180 mg) was carried out to assess dose‐limiting toxicity (DLT), maximum tolerated dose, and pharmacokinetics. Pharmacodynamic markers (serum phosphate, fibroblast growth factor 23, and 1,25‐(OH)2‐vitamin D) were also evaluated. A total of 24 patients refractory to standard therapy or for whom no appropriate treatment was available were enrolled. No DLT were observed up to the 140‐mg dose; one patient in the 180‐mg cohort experienced a DLT (increased aspartate aminotransferase/alanine aminotransferase, grade 3). The maximum tolerated dose was not reached. Dose‐dependent increases in the maximum concentration and area under the curve from time 0 to the last measurable concentration were observed up to 180 mg. Dose‐dependent increases were observed in all pharmacodynamic markers and plateaued at 100‐140 mg, indicating sufficient FGFR pathway inhibition at doses ≥100 mg. In conclusion, E7090 showed a manageable safety profile with no DLT at doses ≤140 mg. Maximum tolerated dose was not determined. The recommended dose for the follow‐up expansion part, restricted to patients with tumors harboring FGFR alterations, was determined as 140 mg, once daily. 相似文献
32.
ABSTRACT
Introduction
Acne is a chronic, inflammatory, and immune mediated disease of pilosebaceous unit, highly prevalent in adolescents. It involves face, trunk, and back; may leave scars and affect quality of life. Early, effective, and safe treatment is the key for disease resolution. Oral isotretinoin is the unique treatment for cure or prolonged remission for moderate and severe acne, preventing psychosocial impact and scars. It inhibits sebaceous glands activity and has anti-inflammatory and immunoregulatory properties. 相似文献33.
目的探究急诊护理临床带教中采用情景模拟、案例讨论联合教学法效果。方法在本院实习的若干名护生中,选取124名护生分按照教学方法分组,对照组62名实施传统急诊护理带教,观察组62名实施案例讨论、情景模拟联合教学法,对比临床带教效果。结果两组实践与理论成绩相比,观察组成绩更高(P<0.05)。思维、急救及应激能力自我评价相比,观察组的总提高率高于对照组(P<0.05)。实施案例分析结合情景模拟教学模式后,问卷调查中观察组无护生不赞同此模式,非常赞同此教学模式的护生占总人数的90%以上。结论实施案例讨论、情景模拟联合教学模式后,护生急诊护理实践与理论水平均提升,护生我评价较高。 相似文献
34.
赵阳 《中国继续医学教育》2020,(4):142-144
目的分析米非司酮和宫瘤消胶囊的联合应用对子宫肌瘤的临床治疗效果。方法本研究对象为80例子宫肌瘤患者,收治时间均在2017年3月—2018年3月期间。将上述子宫肌瘤患者随机分成两组,各40例。给予对照组患者口服米非司酮进行治疗,研究组患者在上述治疗的基础上增加宫瘤消胶囊口服治疗,记录2组患者治疗效果,性激素水平及子宫体积及肿瘤体积变化。结果(1)研究组患者的总体有效率显著高于对照组;(2)研究组患者的P、E2、LH及FSH均显著低于对照组;(3)研究组患者子宫体积及肿瘤体积均显著低于对照组。结论米非司酮片和宫瘤消胶囊的联合治疗对子宫肌瘤患者的治疗效果较显著。 相似文献
35.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
36.
37.
Randomized controlled trials, being published in English and investigating the associations of at least 4 weeks intervention of citrus and/or its extracts on weight loss among adults, were searched from PubMed, Web of Science, Scopus, and Cochrane by June 2019 to conduct a meta‐analysis. Thirteen articles, including 921 participants, were selected and evaluated by modified Jadad scale. Pooled results by the random‐effects model showed that citrus and/or its extracts administration significantly reduced 1.280 kg body weight (95% CI: ?1.818 to ?0.741, p = 0.000, I2 = 81.4%), 0.322 kg/m2 BMI (95% CI: ?0.599 to ?0.046, p = 0.022, I2 = 87.0%), 2.185 cm WC (95% CI: ?3.804 to ?0.566, p = 0.008, I2 = 98.3%), and 2.137 cm HC (95% CI: ?3.775 to ?0.500, p = 0.011, I2 = 96.2%), respectively, but no significantly decreased effects on WHR and body fat were observed. Subgroup analysis deduced the different effects of study location, intervention duration on body weight associated indices. No publication bias was observed. Our meta‐analysis supported the beneficial effects of citrus and/or its extracts supplement on body weight control, and future well‐designed studies are required to firmly establish the clinical efficacy of citrus and/or its extracts intervention on body weight. 相似文献
38.
目的:分析宣威地区与非宣威地区的肺癌临床流行病学与病理特征。方法:以云南省肿瘤医院(昆明医科大学第三附属医院)2015年3月至2015年5月手术治疗的肺癌患者为研究对象,共295例,收集患者相关信息。将其分为宣威地区、非宣威地区进行统计。对患者的临床资料进行回顾性分析,包含病理类型、年龄、性别、吸烟史等。结果:宣威地区、非宣威地区肺癌患者男女比例为1.19∶1和1.69∶1。宣威地区患者平均年龄为[53.41±8.74(34~85)]岁,中位年龄53岁。非宣威地区肺癌患者平均年龄为[58.68±8.63(38~78)]岁,中位年龄59岁。宣威地区肺癌高发年龄为40~59岁段。宣威地区I期肺癌患者占比、T1期肺癌患者占比、N0期肺癌患者占比均高于非宣威地区。宣威地区男性腺癌鳞癌比远高于非宣威地区,差异有显著统计学意义。结论:宣威地区女性肺癌发病率更高,发病年龄更趋年轻化,腺癌比例高,吸烟与宣威地区男性腺癌高发关系不密切。 相似文献
39.
40.
目的分析探讨肿瘤标志物检验在胃癌诊断中的临床价值。方法选择在本院进行治疗的胃癌患者40例,将其列为观察组,选取体检健康者40例,将其列为普通组,具体的选择时间为2018年2月-2019年2月,对两组患者的CEA、CA72-4、CA19-9水平及阳性表达率进行比较分析。结果观察组患者CEA、CA72-4、CA19-9明显高于普通组,差异具有统计学意义(P<0.05)。观察组患者的肿瘤标志物阳性表达率明显高于普通组,差异具有统计学意义(P<0.05)。结论肿瘤标志物在胃癌的诊断中具有非常重要的意义,肿瘤标志物对胃癌患者的诊断较为确切,利于患者的确诊及后期治疗,从而提高患者的生命及生活质量。 相似文献